Alnylam Pharmaceuticals Returns to Profit on Both Reporting Windows Despite Modest Top-Line Lift

Bottom line

The interim filing under accession 0001178670-26-000062 from ALNYLAM PHARMACEUTICALS, INC. (ticker ALNY, CIK 0001178670) is the 10-Q for fiscal period period-ended-2026-06-30. It covers the three-month reporting period the three months ended June 30, 2026 with a prior-year comparison against the three months ended June 30, 2025, and a six-month year-to-date window the six months ended June 30, 2026 with the matching comparative the six months ended June 30, 2025. The lead message for this first section is the swing from a loss to a profit on the bottom line. Net Income (Loss) Attributable to Parent moved from -$72,228,000 for the three months ended June 30, 2025 to $164,494,000 for the three months ended June 30, 2026 — an authorized transition from loss to profit and an authorized direction of increase. The same transition shows up at the year-to-date level, with Net Income (Loss) Attributable to Parent moving from -$90,479,000 for the six months ended June 30, 2025 to $370,485,000 for the six months ended June 30, 2026. Earnings Per Share, Diluted tracks the same shape: -$0.55 per diluted share for the three months ended June 30, 2025 versus $1.21 per diluted share for the three months ended June 30, 2026, and -$0.7 per diluted share for the six months ended June 30, 2025 versus $2.71 per diluted share for the six months ended June 30, 2026 — both window pairs reflect an authorized transition from loss to profit and an authorized direction of increase. Operating Income (Loss) is positive in the current three-month period at $231,441,000, against an operating loss of -$16,199,000 a year earlier, also a loss-to-profit transition. At the six-month level, Operating Income (Loss) is $500,077,000 versus $1,878,000 — a profit-to-profit comparison with an authorized direction of increase. Revenue from Contract with Customer, Excluding Assessed Tax runs higher than the prior period on both windows: $1,290,948,000 for the three months ended June 30, 2026 against $773,689,000 for the three months ended June 30, 2025, and $2,458,123,000 for the six months ended June 30, 2026 against $1,367,878,000 for the six months ended June 30, 2025, each with an authorized direction of increase.

The source scope is the financial statements and notes contained in this 10-Q filing alone; the analysis above is grounded strictly in those reported figures. No prior-quarter, full-year, or annual-report figures are introduced here. The cited note on Stockholders' equity (Note 12) and the cited note on Convertible Debt and Other Financing (Note 8) support the capital-structure context referenced later in this series. The summary of significant accounting policies (Note 2) and the forward-looking risk discussion under Item (omitted) (Item 1A) provide additional context for interpreting the period. Pipeline context is limited to the disclosed hypertension program in the cited clinical development phase (Phase 3). The filing evidence does not attribute this change to any single cause. The filing evidence contains no peer or industry comparison. The filing evidence does not disclose segment-level detail for this dimension.

Financial performance

Across both reporting windows the bottom-line picture shifted from a loss to a profit relative to the prior-year comparatives. Net Income (Loss) Attributable to Parent moved from a deficit for the three months ended June 30, 2025 and the six months ended June 30, 2025 into a positive result for the three months ended June 30, 2026 and the six months ended June 30, 2026, and the same loss-to-profit pattern shows through in Earnings Per Share, Diluted across both windows. Operating Income (Loss) was a loss for the three months ended June 30, 2025 and turned into a profit for the three months ended June 30, 2026, while remaining profitable at a higher level for the six months ended June 30, 2026 than for the six months ended June 30, 2025. Revenue from Contract with Customer, Excluding Assessed Tax rose on both windows, higher in the current the three months ended June 30, 2026 than in the three months ended June 30, 2025 and higher in the six months ended June 30, 2026 than in the six months ended June 30, 2025. The accounting framing is interim GAAP, presented as unaudited condensed consolidated financial statements on a basis substantially consistent with the audited annual statements referenced via Note 2. The filing evidence does not attribute this change to any single cause.

QOQ

The interim statements report the the three months ended June 30, 2026 and the the six months ended June 30, 2026 year-to-date window against the prior-year comparatives; the evidence in this section does not present a sequential three-month-to-three-month view, so a quarter-on-quarter movement is not stated here. Reported facts cover the three-month period and the six-month year-to-date period each against its prior-year comparative, not against an immediately preceding quarter, and that adjacent-quarter comparison is therefore The filing evidence contains no peer or industry comparison. in this section. The half-year window aggregates the same three-month period that is reported separately, so the half-year figures sit alongside the three-month figures rather than acting as a comparison between them. Net Income (Loss) Attributable to Parent and Earnings Per Share, Diluted for the six months ended June 30, 2026 reconcile in direction with the the three months ended June 30, 2026 period, both showing a profit against the prior-year losses, and Revenue from Contract with Customer, Excluding Assessed Tax and Operating Income (Loss) likewise align between the two reported windows. The filing evidence does not attribute this change to any single cause.

GUIDANCE EXPECTATIONS

The narrative cautions that forward-looking statements are subject to risks described in Item 1A "Risk Factors," and that actual results may differ materially from current expectations for reasons the company does not enumerate. Management reiterates its commitment to a multi-product, global commercial biopharmaceutical strategy built on RNAi therapeutics, with six marketed products disclosed as of the report date (including two commercialized by collaborators) and worldwide product revenues currently generated from four commercialized products, primarily in the United States and Europe. No quantified forward guidance for revenue, earnings, margins, or cash flows appears in this section's evidence. Collaborator programs are referenced through Phase 3, describing a development program under the Roche Agreement for the treatment of hypertension, but no revenue or earnings expectation for that program is stated here. Capital structure context is limited to a reference in Note 8 to the Revolving Credit Facility and convertible debt disclosures, and Note 12 covers stockholders' equity components; neither provides a quantified outlook. The filing evidence does not attribute this change to any single cause.

Cross-window baselines that frame the period are restricted to revenue, operating income, net income, and diluted EPS for the three months ended June 30, 2026 and the six months ended June 30, 2026, each compared with its prior-year comparative, and no segment-level breakdown is provided in the cited evidence: The filing evidence does not disclose segment-level detail for this dimension.. For situational context on interim loss-to-profit flips, a parallel pharmaceutical example can be reviewed at Lizely Finance Earnings Analysis — ANI Pharmaceuticals Interim Filing: Profit-to-Profit Growth on Both Windows, though that reference concerns a different issuer and does not provide peer financials for ALNYLAM PHARMACEUTICALS, INC..

Operating drivers and segments

- Reported Revenue from Contract with Customer, Excluding Assessed Tax for the three-month reporting period is positive, with the prior-year comparative also positive and lower; the authorized direction is an increase, characterizing a revenue lift rather than a margin reclassification. - Reported Revenue from Contract with Customer, Excluding Assessed Tax for the six-month year-to-date period is positive and authorized to have increased over a positive prior-year comparative, leaving the top line expanded on both windows even before cost detail is examined. - Reported Operating Income (Loss) for the three-month reporting period is positive while the prior-year comparative was a loss, marking an authorized transition from loss to profit on a single-quarter basis. - Reported Operating Income (Loss) for the six-month year-to-date period is positive and authorized to have increased versus a positive prior-year comparative, consistent with profit-to-profit growth on the half-year window. - The filer identifies product franchises by name — AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO, plus collaborator-marketed Leqvio, Qfitlia and cemdisiran — but reports them within a single consolidated revenue line rather than as discrete segment disclosures; the cited note does not present reportable segment margin detail. - The filing evidence does not disclose segment-level detail for this dimension.

- Management frames the period inside a multi-year strategic plan referred to as the "Alnylam (omitted)" strategy, linking forward-looking commentary about revenue, expenses, margins, profitability, cash flows and capital expenditures to that framework rather than to a single quarter's drivers. - The discussion casts the named therapeutic and collaborator programs as the vehicles through which future financial performance is expected to be delivered, listing them in sequence rather than assigning quantified segment contributions; no product-level revenue breakout is provided in the excerpt. - Management ties operational continuity to collaborators and contract manufacturers for supply of AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO and the partner-marketed products, signaling that near-term execution risk is presented as a partner-and-manufacturing question rather than a demand question. - The commentary also directs readers to background context covered by Note 2 for significant accounting policies and to Note 8 for convertible debt and revolver information, indicating that margin commentary is anchored to existing policy footnotes rather than new disclosures. - The filing evidence does not attribute this change to any single cause.

Cash flow and capital

- Reported facts (operating, investing, and financing activity for the six-month year-to-date window): - Net cash provided by operating activities totaled $397,228,000 USD for the period covering the six months ended June 30, 2026, versus $9,495,000 USD for the prior-year comparative window covering the six months ended June 30, 2025; the period-over-period comparison is a direction increase, with both windows reflecting a positive inflow. - Net cash used in investing activities was -$388,999,000 USD for the six months ended June 30, 2026, versus -$27,612,000 USD for the six months ended June 30, 2025; the comparison is a direction decrease, with both windows reflecting a negative outflow.

- Net cash provided by financing activities was $51,951,000 USD for the six months ended June 30, 2026, versus $123,762,000 USD for the six months ended June 30, 2025; the comparison is a direction decrease, with both windows reflecting a positive inflow. - Payments to acquire property, plant, and equipment were $56,513,000 USD for the six months ended June 30, 2026 and $23,263,000 USD for the six months ended June 30, 2025; the comparison is a direction increase, with both windows reflecting a positive outflow. - Management explanation on liquidity and capital needs: - Management states that, based on its current operating plan, the company's cash, cash equivalents, marketable securities, expected revenue from product sales and existing collaborations (including royalties on Leqvio and Qfitlia), and available borrowing capacity under the revolving credit agreement as of the balance sheet date of June 30, 2026 are expected to be sufficient to satisfy near-term capital and operating needs for at least the next twelve months from the filing date of this 10-Q for ALNYLAM PHARMACEUTICALS, INC..

- For further detail on the Revolving Credit Agreement, management refers readers to Note 8. - Balance sheet items supporting the liquidity commentary: - Cash and cash equivalents, at carrying value, stood at $1,708,318,000 USD as of the balance sheet date of June 30, 2026. - Accounts receivable, after allowance for credit loss, were $912,739,000 USD as of the balance sheet date of June 30, 2026.

- Accounts payable, current, were $108,016,000 USD as of the balance sheet date of June 30, 2026. - Analyst inference: - The combination of a direction increase in operating cash flow alongside a continuing investing outflow is consistent with a profile where commercial cash generation is being plowed back into the business, including via a direction increase in property, plant, and equipment spending relative to the prior-year comparative. - A direction decrease in financing cash flow against a still-positive base suggests the prior-year comparative window captured a larger gross financing inflow; the relative pullback this window leaves financing as a smaller source of liquidity rather than a user of cash.

- The size of the on-balance-sheet cash position relative to short-term trade items (receivables versus payables) is consistent with the management assertion of adequate near-term liquidity. - Counter-evidence and unknowns: - The filing evidence does not break investing outflows into capital expenditure versus portfolio activity, so the magnitude of cash reinvested beyond the property, plant, and equipment line cannot be read directly. - The filing evidence does not disclose segment-level cash flow detail.

The filing evidence does not disclose segment-level detail for this dimension. - The filing evidence contains no peer or industry comparison for these cash flow and capital allocation metrics. The filing evidence contains no peer or industry comparison.

- The filing evidence does not attribute the direction changes in operating, investing, financing, or capital expenditure cash flows to any single cause. The filing evidence does not attribute this change to any single cause. - Stockholders' equity disclosure, including preferred stock terms, is referenced in Note 12, but specific equity-roll-forward figures are outside this section's catalog.

Peer and historical context

- Looking at the filing's own year-over-year comparisons, the most striking historical shift is on the income statement. For both the three-month reporting period and the six-month year-to-date period, Net Income (Loss) Attributable to Parent moved from a loss in the prior year to a profit in the current year — an authorized loss-to-profit transition that can be asserted without my own direction or cause. - Operating Income (Loss) shows the same pattern on the quarter window: a loss in the prior-year quarter becomes a profit in the current quarter. On the six-month window, Operating Income (Loss) was already profitable in the prior year and remains profitable in the current year. - Revenue from Contract with Customer, Excluding Assessed Tax rose on both windows relative to the prior-year comparatives, which is consistent with the product-collaboration commentary in the filing that names royalties tied to sales of Leqvio and Qfitlia alongside the Roche strategic collaboration on zilebesiran, currently in the cited phase-three hypertension program. - Net Cash Provided by (Used in) Operating Activities also increased on the six-month window relative to the prior-year comparative, again an authorized direction only.

- Despite the income statement improvement, the cash-flow statement still tells a cautious story. The company describes its liquidity position as sufficient to satisfy near-term capital and operating needs only for the next several months from the filing date, with reliance on the Revolving Credit Agreement referenced in the cited convertible-debt note. That is a self-imposed short horizon, not an open-ended runway. - The forward-looking disclosures also flag a recent accounting pronouncement — the cited targeted improvements to internal-use software — that the company says it is currently evaluating, leaving the magnitude of any future impact unstated. - Investors weighing the loss-to-profit swing should remember that the prior-period comparables were losses, so a swing into profitability can reflect a comparatively easy base rather than a structural margin shift; the filing itself does not attribute the swing to any single cause.

The filing evidence does not attribute this change to any single cause.

The filing evidence contains no peer or industry comparison.

Scenario analysis

- Reported facts: Revenue from Contract with Customer, Excluding Assessed Tax for the three months ended June 30, 2026 is $1,290,948,000 USD and for the six months ended June 30, 2026 is $2,458,123,000 USD, each higher than the prior-year comparative. Net Income (Loss) Attributable to Parent for the three months ended June 30, 2026 is $164,494,000 USD and for the six months ended June 30, 2026 is $370,485,000 USD, each a profit rather than the prior-period loss shown at -$72,228,000 USD and -$90,479,000 USD. Management explains liquidity by reference to cash, cash equivalents, marketable securities, expected product sales, royalties on sales of Leqvio and Qfitlia, and the Revolving Credit Agreement referenced in Note 8, stating that this capital mix is expected to satisfy near-term capital and operating needs for at least the next twelve months from the filing date of 10-Q. Analyst inference: in a base outcome these revenue and net-income readings continue along their current directional paths, supported by the cited liquidity runway. Counter-evidence: none disclosed in the filing. Unknowns: forward quarter-by-quarter revenue cadence. - Assumptions a reader should test against the cited note and the period-end cash position.

- Reported facts: Revenue recognized in both windows continues to grow versus $1,367,878,000 USD and $773,689,000 USD, and Net Income (Loss) Attributable to Parent remains in profit territory at $370,485,000 USD and $164,494,000 USD. Management explanations highlight ongoing collaborations, including the worldwide strategic collaboration with Roche covering zilebesiran, which is currently in Phase 3 clinical development for the treatment of hypertension, as a potential additional source of future consideration. Analyst inference: any favourable read-through to revenue and net income would be amplified if the collaboration advances as planned and royalties on sales of Leqvio and Qfitlia expand. The filing evidence contains no peer or industry comparison. Counter-evidence: Item 1A cautions that risk factors discussed elsewhere in this Quarterly Report on Form could derail the path. Unknowns: clinical-programme timing and any future milestone economics not disclosed in this filing.

- Reported facts: trailing comparatives show a prior-year net loss at -$90,479,000 USD and -$72,228,000 USD against current profits of $370,485,000 USD and $164,494,000 USD, illustrating that the income recovery is recent rather than entrenched. Management explanations acknowledge that forward revenue depends on product sales, existing collaborations, royalties, and the Revolving Credit Agreement referenced in Note 8. Analyst inference: a reversal to the prior loss profile is plausible if those revenue and collaboration streams weaken. Counter-evidence: risk-factor language under Item 1A and the issuance of new accounting guidance such as the targeted improvements to internal-use software accounting flagged in management's recent-accounting-pronouncements discussion highlight ongoing policy and operational change. Unknowns: post-period revenue trajectory. The filing evidence does not attribute this change to any single cause.

Risks and what to watch

- Risks highlighted in the filing begin with the standard cautionary language in the cited note, where management frames the company as subject to a range of operational, regulatory, and competitive uncertainties typical of an early-commercial biopharmaceutical issuer. The reference to ongoing development activity, including a Phase program described in the cited note for the treatment of hypertension under the Roche Agreement, signals continued reliance on clinical and partnership outcomes as a forward driver. Debt-related obligations are also flagged through the cited note on convertible debt and other financing, which mentions the Revolving Credit Facility, reminding readers that liquidity tools and covenants remain part of the risk picture.

- Counter-evidence to the profit swing on the bottom line is visible in the prior-period comparatives. For the three-month reporting period, Net Income (Loss) Attributable to Parent moved from a loss in the prior-year comparative to a profit in the current period, and the same loss-to-profit transition is present on the six-month year-to-date basis. That said, profitability remains narrow when read against Revenue from Contract with Customer, Excluding Assessed Tax, which on the three-month window is roughly flat against the prior-year comparative and only moderately higher on the six-month year-to-date basis.

The gap between the sharp swing in earnings and the more measured revenue trajectory is a counter-signal that the headline profit improvement does not fully reflect a comparable top-line re-rating, and the filing evidence does not attribute this change to any single cause. - Unknowns include the timing and magnitude of any accounting impact from the standard updates referenced in the source narrative, where management notes the standard may be applied on a prospective, retrospective, or modified retrospective approach and that the impact is still being evaluated.

The filing language also points to a clarifying update that the standard will be effective for annual reporting periods beginning after December (omitted) and interim reporting periods beginning after December (omitted) with early adoption permitted, leaving the adoption path open. Readers cannot yet gauge the income-statement or disclosure effect of these updates from the filing evidence, and the cited note on stockholders' equity leaves preferred-share terms defined by par value per share rather than by an explicit yield or conversion mechanic that this section could quantify.

- Metrics to watch next period begin with Revenue from Contract with Customer, Excluding Assessed Tax on both the three-month and six-month year-to-date bases, since top-line durability is the clearest forward tell for whether the earnings swing can be sustained. Net Income (Loss) Attributable to Parent on the same two windows is the second anchor, alongside operating cash flow direction, since cash generation will indicate whether accounting profit is converting into liquidity after the convertible-debt-related obligations referenced in the cited note.

Readers comparing interim filings can also contrast the pattern with REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in period-ended-2026-06-30 Filing to gauge how a profit-to-profit revenue trajectory differs from the loss-to-profit pattern visible here.